Global TMJ Disorders Market Research Report—Forecast till 2027

$4,450$6,250

Global TMJ Disorders Market was valued at USD 650.07 Million in 2019 and is expected to register a CAGR of 4.18 % during the forecast period of 2020 to 2027. T

Clear

Description

Global TMJ Disorders Market Research Report—Forecast till 2027
Market Overview
Global TMJ Disorders Market was valued at USD 650.07 Million in 2019 and is expected to register a CAGR of 4.18 % during the forecast period of 2020 to 2027. Temporomandibular joint and muscle disorders are referred to as TMJ disorder that causes pain in the muscles and joints jaw. The increasing introduction and rapid adoption of advanced treatments and easy availability of medicines, rising prevalence of TMJ disorders, and increase in healthcare expenditure are expected to propel the market growth during the review period.

The global TMJ Disorder Market is expected to register a healthy market growth owing to the increase in technological advancement and increasing prevalence of these disorders. The emergence of non-surgical and surgical treatment methods for TMJ disorders is expected to drive market growth during the review period. TMJ disorders are the second-most commonly occurring musculoskeletal conditions resulting in pain and disability. The occurrences of TMD peaks from the age of 20-40 years, and it is found to be more prevalent in women than men. Additionally, women who use supplemental estrogenic or oral contraceptives are more expected to seek treatment for these conditions. Therefore, the increasing prevalence of these disorders in these populations is further fuelling the market growth during the review period.
Market Segmentation
The Global TMJ Disorders Market has been classified into Type, treatment, and end-user.
Based on type segment, the Global TMJ Disorders Market, based on Type classified into myofascial Pain, Internal Derangement (ID), and Osteoarthritis.
In terms of treatment, the market has been divided into medication, therapies, surgical, and others. The medication segment is further sub-divided into pain relievers, anti-inflammatories, tricyclic antidepressants, muscle relaxants, and others.
Based on end-user, the global TMJ disorders market is segmented into hospitals and clinics, ambulatory surgery centers, academic institutes, and others.
Regional Analysis
Geographically, the Global TMJ Disorder Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas market has been divided into North America and Latin America, with the North America market further segmented into the US and Canada. The Americas is expected to dominate the global market owing to the largest share of 49.20% of the TMJ disorder market in 2019. This largest share is driven by the introduction and rapid adoption of advanced treatments in the region.
The European TMJ disorder market has been bifurcated into Western Europe and Eastern Europe. The Western Europe TMJ disorder market has further been divided into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The TMJ disorder market in Asia-Pacific has been classified into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa TMJ disorder market has been segmented into the Middle East and Africa.
Major Players
The key players in the global TMJ Disorders market are Abbott Laboratories, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Allergan, Bayer AG, Zydus Cadila, Mylan NV, Novartis International AG, and Jubilant Life Sciences Limited.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

2.3 MARKET STRUCTURE 15

2.4 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.6.1 BOTTOM-UP APPROACH 23

3.6.2 TOP-DOWN APPROACH 23

3.7 DATA TRIANGULATION 24

3.8 VALIDATION 24

4 MARKET DYNAMICS

4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 GROWING RATES OF PET OWNERSHIP 26

4.2.2 RISING ZOONOTIC & CHRONIC DISEASES ANIMALS 26

4.2.3 INCREASING MEAT CONSUMPTION ATTRACTING MANDATORY VACCINATION 26

4.3 RESTRAINT 27

4.3.1 SHORTAGE OF VETERINARIANS 27

4.3.2 STRINGENT REGULATORY GUIDELINES PERTAINING TO VACCINES APPROVAL FOR ANIMALS 27

4.4 OPPORTUNITY 28

4.4.1 INCREASING INVESTMENT IN VETERINARY HOSPITALS 28

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 R&D 30

5.1.2 MANUFACTURING 30

5.1.3 DISTRIBUTION & SALES 30

5.1.4 POST-SALES REVIEW/MONITORING 30

5.2 PORTER’S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 31

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 32

5.2.4 BARGAINING POWER OF BUYERS 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 IMPACT OF COVID-19 32

5.3.1 OVERVIEW 32

5.3.2 IMPACT ON MEAT CONSUMPTION 33

5.3.3 IMPACT ON VETERINARY MEDICINE MARKET 33

6 GLOBAL VETERINARY MEDICINE MARKET, BY ANIMAL TYPE

6.1 OVERVIEW 34

6.2 DOMESTICATED 35

6.3 COMPANION 35

7 GLOBAL VETERINARY MEDICINE MARKET, BY PRODUCT

7.1 OVERVIEW 37

7.2 DRUG 38

7.3 VACCINES 39

8 GLOBAL VETERINARY MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW 40

8.2 ORAL 41

8.3 PARENTERAL 41

8.4 OTHERS 42

9 GLOBAL VETERINARY MEDICINE MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW 43

9.2 VETERINARY HOSPITALS & CLINICS 44

9.3 RETAIL STORES 44

9.4 ONLINE PHARMACIES 45

10 GLOBAL VETERINARY MEDICINE MARKET, BY REGION

10.1 OVERVIEW 46

10.2 AMERICAS 48

10.2.1 NORTH AMERICA 50

10.2.1.1 US 52

10.2.1.2 CANADA 53

10.2.2 LATIN AMERICA 54

10.3 EUROPE 56

10.3.1 WESTERN EUROPE 58

10.3.1.1 GERMANY 60

10.3.1.2 UK 61

10.3.1.3 FRANCE 62

10.3.1.4 ITALY 63

10.3.1.5 SPAIN 64

10.3.1.6 REST OF WESTERN EUROPE 65

10.3.2 EASTERN EUROPE 67

10.4 ASIA-PACIFIC 69

10.4.1 CHINA 71

10.4.2 JAPAN 72

10.4.3 INDIA 73

10.4.4 AUSTRALIA 74

10.4.5 SOUTH KOREA 75

10.4.6 REST OF ASIA-PACIFIC 76

10.5 MIDDLE EAST & AFRICA 78

10.5.1 SAUDI ARABIA 80

10.5.2 UNITED ARAB EMIRATES 81

10.5.3 OMAN 83

10.5.4 KUWAIT 84

10.5.5 QATAR 85

10.5.6 REST OF THE MIDDLE EAST & AFRICA 86

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 88

11.2 COMPETITIVE BENCHMARKING 89

11.3 GLOBAL VETERINARY MEDICINE MARKET: COMPANY RANKING 90

11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 91

11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL VETERINARY MEDICINE MARKET 91

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 92

11.6.1 NEW PRODUCT LAUNCHES 92

11.6.2 PARTNERSHIPS/AGREEMENTS 92

11.6.3 EXPANSIONS 93

11.6.4 ACQUISITIONS 93

11.7 FINANCIAL MATRIX 94

12 COMPANY PROFILES

12.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 96

12.1.1 COMPANY OVERVIEW 96

12.1.2 FINANCIAL OVERVIEW 97

12.1.3 PRODUCTS/SERVICES OFFERED 97

12.1.4 KEY DEVELOPMENTS 99

12.1.5 SWOT ANALYSIS 99

12.1.6 KEY STRATEGIES 100

12.2 CEVA 101

12.2.1 COMPANY OVERVIEW 101

12.2.2 FINANCIAL OVERVIEW 101

12.2.3 PRODUCTS/SERVICES OFFERED 102

12.2.4 KEY DEVELOPMENTS 102

12.2.5 SWOT ANALYSIS 103

12.2.6 KEY STRATEGIES 103

12.3 ZOETIS 104

12.3.1 COMPANY OVERVIEW 104

12.3.2 FINANCIAL OVERVIEW 104

12.3.3 PRODUCTS/SERVICES OFFERED 105

12.3.4 KEY DEVELOPMENTS 107

12.3.5 SWOT ANALYSIS 107

12.3.6 KEY STRATEGIES 107

12.4 MERCK ANIMAL HEALTH 108

12.4.1 COMPANY OVERVIEW 108

12.4.2 FINANCIAL OVERVIEW 109

12.4.3 PRODUCTS/SERVICES OFFERED 110

12.4.4 KEY DEVELOPMENTS 111

12.4.5 SWOT ANALYSIS 112

12.4.6 KEY STRATEGIES 112

12.5 CHANELLE PHARMA GROUP 113

12.5.1 COMPANY OVERVIEW 113

12.5.2 FINANCIAL OVERVIEW 113

12.5.3 PRODUCTS/SERVICES OFFERED 113

12.5.4 KEY DEVELOPMENTS 115

12.5.5 SWOT ANALYSIS 115

12.5.6 KEY STRATEGIES 115

12.6 ELANCO 116

12.6.1 COMPANY OVERVIEW 116

12.6.2 FINANCIAL OVERVIEW 117

12.6.3 PRODUCTS/SERVICES OFFERED 118

12.6.4 KEY DEVELOPMENTS 119

12.6.5 SWOT ANALYSIS 120

12.6.6 KEY STRATEGIES 120

12.7 DECHRA PHARMACEUTICALS PLC 121

12.7.1 COMPANY OVERVIEW 121

12.7.2 FINANCIAL OVERVIEW 121

12.7.3 PRODUCTS/SERVICES OFFERED 122

12.7.4 KEY DEVELOPMENTS 123

12.7.5 SWOT ANALYSIS 123

12.7.6 KEY STRATEGIES 123

12.8 BAYER AG 124

12.8.1 COMPANY OVERVIEW 124

12.8.2 FINANCIAL OVERVIEW 124

12.8.3 PRODUCTS/SERVICES OFFERED 125

12.8.4 KEY DEVELOPMENTS 126

12.8.5 SWOT ANALYSIS 127

12.8.6 KEY STRATEGIES 127

12.9 VETOQUINOL SA. 128

12.9.1 COMPANY OVERVIEW 128

12.9.2 FINANCIAL OVERVIEW 128

12.9.3 PRODUCTS/SERVICES OFFERED 129

12.9.4 KEY DEVELOPMENTS 131

12.9.5 SWOT ANALYSIS 132

12.9.6 KEY STRATEGIES 132

12.10 NORBROOK LABORATORIES 133

12.10.1 COMPANY OVERVIEW 133

12.10.2 FINANCIAL OVERVIEW 133

12.10.3 PRODUCTS/SERVICES OFFERED 133

12.10.4 KEY DEVELOPMENTS 135

12.10.5 SWOT ANALYSIS 135

12.10.6 KEY STRATEGIES 136

13 APPENDIX

13.1 REFERENCES 137

13.2 RELATED REPORTS 138